Stifel reiterated its Buy rating on Definium Therapeutics (NASDAQ: DFTX) following a management dinner, citing strong efficacy data and commercial prospects for the company’s lead candidate, DT120.
The oral dissolving tablet, designed to treat generalized anxiety disorder (GAD) and major depressive disorder (MDD), has gained significant attention after Phase 3 results demonstrated statistically significant reductions in Hamilton Anxiety Rating Scale scores. Stifel’s price target range for Definium remains between $52 and $90, underscoring the drug’s potential as a blockbuster therapy.
Definium’s stock has surged 206% over the past year, closing at $40.98 on Tuesday, down 6.48% in the session. The company’s market capitalization stands at $5.51 billion, with pre-market trading indicating a slight pullback to $40.805.
Analysts at Canaccord Genuity upgraded their target to $64 from $58 while maintaining a Buy rating. BofA Securities initiated coverage with a Buy rating and a $75 price target, reflecting growing confidence in the drug’s commercial viability.
Definium’s financials for the second quarter of 2026 show rising costs, with research and development expenses climbing to $48.7 million from $29.8 million a year earlier. General and administrative costs also increased to $26.4 million from $11.1 million. The net loss widened to $159 million, driven largely by a non-cash warrant revaluation expense of $86.2 million.
The company’s Phase 3 Voyage study met its primary and key secondary endpoints, demonstrating DT120’s anxiolytic effects independent of mood benefits. Regulatory alignment has been secured for potential approvals in both GAD and MDD based on current data.
A second study, Panorama, is expected to release data in September, with statistical analysis comparing a 100 mcg dose to a placebo. A 50 mcg group is included to address patient expectation and potential functional unmasking concerns, though management noted it does not need to establish efficacy for this lower dose.
